Exblifep (cefepime/enmetazobactam) / Allecra - LARVOL DELTA

Diagnostic algorithm for the detection of carbapenemases and extended-spectrum β-lactamases in carbapenem-resistant Pseudomonas aeruginosa. (PubMed, Microbiol Spectr) - "We used the following BL-BLI combinations: ceftolozane-tazobactam (C-T), ceftazidime-avibactam, imipenem-relebactam (I-R), meropenem-vaborbactam, cefepime-enmetazobactam (C-E), and aztreonam-avibactam. This method is particularly valuable for laboratories lacking access to molecular diagnostics, as it provides a practical alternative for routine testing. By facilitating the early detection of resistant P. aeruginosa strains, this approach has the potential to improve patient outcomes, optimize antimicrobial therapy, and enhance global surveillance efforts against multidrug-resistant pathogens."

Journal • Infectious Disease

Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow. (PubMed, Expert Rev Anti Infect Ther) - "A literature search was performed on PubMed-MEDLINE (until December 2024) for retrieving available studies on cefepime-enmetazobactam, sulbactam-durlobactam, and cefepime-taniborbactam. Overall, old habits die hard and issues retrieved with licensed beta-lactams emerged also with novel BL/BLIc of tomorrow, potentially affecting their efficacy when used in real-world practice. Adopting appropriate corrective measures for overcoming these issues might increase the likelihood of preserving their efficacy in the future by minimizing the propensity risk of resistance development."

Clinical • Journal • Infectious Disease • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases

Cefepime/enmetazobactam as treatment for extended-spectrum-betalactamase producing Escherichia coli bloodstream infection in a septic patient with liver cirrhosis: a case report (ESCMID Global 2025) - No abstract available

Case report • Clinical • Fibrosis • Gastroenterology • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis

Microbiological outcome of eradication of cefepime/enmetazobactam vs piperacillin/tazobactam against most common Enterobacterales at test of cure; a posthoc analysis from the ALLIUM Phase 3 trial (ESCMID Global 2025) - No abstract available

P3 data • Retrospective data

Outcomes by MIC values for patients infected with Enterobacterales treated with cefepime/enmetazobactam or piperacillin/tazobactam for complicated urinary tract infections in the phase 3 ALLIUM trial (ESCMID Global 2025) - No abstract available

Clinical • P3 data • Infectious Disease • Nephrology

Cefepime/enmetazobactam for Gram-negative PJIs? A porcine study evaluating target tissue concentrations following intermittent short-term infusion and continuous infusion of a novel antibiotic combination (ESCMID Global 2025) - No abstract available

Gram negative • Preclinical • Infectious Disease

Impact of bacterial inoculum on the activity of cefepime and cefepime/enmetazobactam against AmpC-hyperproducing Enterobacter spp (ESCMID Global 2025) - No abstract available

Cefepime/enmetazobactam as a carbapenem-sparing alternative: activity against extended-spectrum beta-lactamase-producing Enterobacteriaceae, with or without carbapenemases (ESCMID Global 2025) - No abstract available

Effect of cefepime/enmetazobactam (FEP-META) versus ceftazidime/avibactam (CAZ-AVI) in combination with aztreonam (ATM) against clinical isolates resistant to different β-lactamase classes (ESCMID Global 2025) - No abstract available

Clinical • Combination therapy

Influence of outer membrane permeability and KPC amino acid variation on the activity of cefepime/enmetazobactam against KPC-producing Enterobacterales showing ceftazidime/avibactam resistance (ESCMID Global 2025) - No abstract available

Activity of cefepime/enmetazobactam in highly resistant Gram-negative bacteria in a tertiary care setting in Germany (ESCMID Global 2025) - No abstract available

Gram negative • Infectious Disease

In vitro efficacy of cefepime/enmetazobactam against AmpC beta-lactamase-producing Enterobacterales (ESCMID Global 2025) - No abstract available

Preclinical

In vitro activity of cefepime/enmetazobactam and comparators against ESBL and plasmid-AmpC-producing Enterobacterales (ESCMID Global 2025) - No abstract available

Preclinical

Evaluation of cefepime/enmetazobactam efficacy against BLEE + OXA 48 resistant strains (ESCMID Global 2025) - No abstract available

Clinical

Activity of the novel beta-lactam/beta-lactamase inhibitor combination cefepime/enmetazobactam against Acinetobacter spp. (ESCMID Global 2025) - No abstract available

IPT17 - Physicochemical stability of cefepime/emmetazobactam in medical devices for continuous infusion. Is it possible to use it in OPAT? (ESCMID Global 2025) - "Stability data are required for continuous infusion. At Advanz we have carried out a pre-clinical development to generate physicochemical stability data on different medical devices and at different conditions to understand the potential use of cefepime-enmetazobactam in continuous infusions and for it use in OPAT."

In vitro activity of cefepime/enmetazobactam against clinical isolates of Enterobacterales in Portugal: A multicentre retrospective study (ESCMID Global 2025) - No abstract available

Preclinical • Retrospective data

'In vitro activity of cefepime-enmetazobactam on carbapenem resistant Gram negatives' - Author's reply. (PubMed, Clin Microbiol Infect) - No abstract available

Journal • Preclinical • Infectious Disease

Antimicrobial activity of cephamycins and β-lactam/β-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula. (PubMed, Sci Rep) - "At the higher inoculum size, cefoxitin, cefmetazole, flomoxef, ceftolozane/tazobactam, ceftazidime/avibactam, cefepime/enmetazobactam, and imipenem/relebactam demonstrated in vitro efficacy against 48.3%, 75.9%, 70.0%, 0%, 82.8%, 100%, 89.7% of the ESBL-producing isolates. Cephamycins demonstrated high in vitro activity against ESBL-producing isolates at standard inoculum sizes. However, the in vitro time-kill experiments revealed that the efficacy of cephamycins is not fully maintained at high inoculum sizes."

Journal • Infectious Disease • Pneumonia

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development. (PubMed, Pathogens) - "The incorporation of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam has provided new therapeutic options in the treatment of patients with infections due to MDR pathogens. Cefiderocol along with cefepime/enmetazobactam, avibactam/aztreonam, and sulbactam/durlobactam have been recently added to these agents as therapeutic choices, particularly for metallo-β-lactamase producing Gram-negative bacteria...However, only a few have advanced through phase 1, 2, and 3 clinical trials. Among them, in this article, we focus on the most promising combinations of cefepime/zidebactam, cefepime/taniborbactam, and imipenem/cilastatin/funobactam, which are currently under investigation in phase 3 trials."

Journal • Review • Infectious Disease

Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales. (PubMed, Future Microbiol) - "The targeted activity of cefepime-enmetazobactam against ESBLs infections which are resistant to common antibiotics, together with its superior results against piperacillin/tazobactam in a phase 3 trial make this new BL/BLI combination an effective carbapenem sparing option for the treatment of serious infections caused by ESBLs-producing Enterobacterales. In addition, if clinical data are supportive, cefepime-enmetazobactam has a potential role in the treatment of pathogens co-producing OXA-48 like enzymes along with ESBLs."

Journal • Review • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

Comparative evaluation of disc diffusion and Liofilchem™ MTS strip methods with broth microdilution for cefepime/enmetazobactam susceptibility testing. (PubMed, J Antimicrob Chemother) - "Disc diffusion and Liofilchem™ MTS strips represent reliable alternatives to BMD for routine cefepime/enmetazobactam testing."

Journal • Infectious Disease

Re: 'In vitro activity of cefepime-enmetazobactam on carbapenem resistant Gram negatives' by Bonnin et al. (PubMed, Clin Microbiol Infect) - No abstract available

Journal • Preclinical • Infectious Disease

Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation. (PubMed, Expert Opin Drug Metab Toxicol) - "The main potential role for cefepime/enmetazobactam is as a carbapenem-sparing agent for the treatment of infections caused by ESBL-producing Enterobacterales to prevent the use of carbapenems and to avoid the toxicities of non-β-lactam alternatives.There may be potential uses for cefepime/enmetazobactam for the treatment of reproductive tract infections, abdominal infections and neonatal sepsis, given the spectrum of activity and pharmacokinetic properties. However, additional non-clinical and clinical studies are required before use in these settings."

Journal • PK/PD data • Review • Infectious Disease • Nephrology • Septic Shock

Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis. (PubMed, J Comp Eff Res) - "For composite outcome at test of cure (TOC), ceftolozane + tazobactam, cefepime + enmetazobactam, cefiderocol, levofloxacin and plazomicin demonstrated significantly higher RRs versus carbapenems. For microbiological eradication at TOC, cefepime + enmetazobactam, plazomicin, cefiderocol, fosfomycin, meropenem + vaborbactam and ceftazidime + avibactam demonstrated significantly higher RRs versus carbapenems. RRs for cefepime + enmetazobactam were also significantly higher versus several established and novel treatment options for composite outcome, microbiological eradication and clinical cure. Against the backdrop of increasing bacterial resistance, these findings suggest that cefepime + enmetazobactam may represent an effective carbapenem-sparing treatment option in patients with cUTI including AP."

Journal • Retrospective data • Infectious Disease • Nephrology